LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

60.41 -0.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

61.94

Põhinäitajad
By Trading Economics
Sissetulek	-14M -105M
Kasumimarginaal	-867.293
Töötajad	358
EBITDA	-15M -104M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+16.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.9B 5.2B
Eelmine avamishind	60.72
Eelmine sulgemishind	60.41

Uudiste sentiment

By Acuity

24%

76%

42 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. märts 2026, 16:12 UTC

Suurimad hinnamuutused turgudel

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

16.12% tõus

12 kuu keskmine prognoos

Keskmine 72.88 USD 16.12%

Kõrge 100 USD

Madal 50 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

42 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.